AI Medical Scribe for Oncology & Hematology

Oncology visits demand your complete emotional presence. When delivering difficult news, monitoring treatment response, or managing chemotherapy side effects, you need to connect with patients—not type into a computer. Yet cancer care generates some of medicine’s most complex documentation: multi-agent regimens with dose modifications, CTCAE adverse event grading, performance status tracking, and treatment response assessments that determine the next therapeutic decision.

OrbDoc’s voice-first medical scribe understands oncology workflows. Speak naturally during chemotherapy visits, follow-up appointments, or survivorship consultations, and receive structured notes that capture treatment cycles, toxicity assessments, and response evaluations—without taking your focus away from the patient sitting across from you during some of the most vulnerable moments of their lives.

Chemotherapy Visit Documentation

Every chemotherapy cycle requires meticulous documentation: current cycle and day, prior treatment tolerance, interval symptoms, laboratory values, dose calculations, and patient education. Traditional EHR documentation interrupts the flow of these time-sensitive visits.

With OrbDoc, oncologists document while examining patients:

“Patient here for cycle three, day one of FOLFOX. Since last visit, she’s had grade two neuropathy in fingertips, no nausea with current antiemetics. Labs today show ANC 1800, platelets 140,000. Discussed dose reduction of oxaliplatin to 75% given peripheral neuropathy. Patient understands and agrees. ECOG performance status remains one.”

OrbDoc structures this into chemotherapy visit documentation:

Treatment Status: Cycle 3, Day 1 of FOLFOX (5-FU, leucovorin, oxaliplatin)

Interval History:

• Peripheral neuropathy: Grade 2 per CTCAE (sensory, fingertips)
• Nausea: Well-controlled with current antiemetic regimen
• No fever, infection, bleeding, or other concerning symptoms

Performance Status: ECOG 1 (ambulatory, restricted in physically strenuous activity)

Laboratory Values:

• ANC: 1,800/μL (adequate for chemotherapy)
• Platelets: 140,000/μL (adequate for chemotherapy)

Treatment Modifications:

• Oxaliplatin dose reduced to 75% (from 85 mg/m² to 64 mg/m²) due to Grade 2 peripheral neuropathy
• 5-FU and leucovorin continued at standard doses

Patient Education:

• Discussed rationale for dose modification
• Reviewed neuropathy precautions (avoid cold exposure, monitor for progression)
• Patient verbalized understanding and agreement with plan

Plan: Proceed with modified FOLFOX today. Reassess neuropathy at next visit. Continue antiemetics as prescribed.

The documentation captures chemotherapy-specific details—cycle numbers, CTCAE grading, performance status, dose calculations, and shared decision-making—while you focus on patient safety and education during treatment administration.

Treatment Response Assessment

Oncology thrives on precision. Tumor measurements, imaging interpretations, progression criteria, and treatment decisions require accurate documentation that supports clinical trials, quality metrics, and critical therapeutic pivots.

During a follow-up visit reviewing imaging:

“CT chest, abdomen, pelvis shows decrease in liver metastases. Lesion in segment six measures 3.2 centimeters, previously 4.8 centimeters. Lung nodule in right lower lobe stable at 1.1 centimeters. No new sites of disease. By RECIST criteria, this represents partial response. Patient tolerating therapy well. Plan to continue current regimen.”

OrbDoc creates structured response assessment documentation:

Imaging Review (CT Chest/Abdomen/Pelvis - [Date]):

Target Lesions:

• Liver segment VI: 3.2 cm (previously 4.8 cm) - 33% reduction
• Right lower lobe lung nodule: 1.1 cm (stable)

Non-Target Lesions: No new lesions identified

Response Assessment: Partial Response per RECIST v1.1 criteria (≥30% decrease in sum of target lesions)

Treatment Tolerance: Patient reports good tolerance of current chemotherapy regimen with manageable side effects

Clinical Decision: Continue current chemotherapy regimen given objective response and acceptable toxicity profile

Next Steps:

• Continue FOLFOX at current doses
• Repeat imaging in 8-10 weeks
• Monitor for progression or new symptoms

This documentation supports tumor board presentations, clinical trial requirements, and insurance authorization while ensuring treatment decisions are clearly justified and tracked over time.

Community Cancer Center Implementation

Community oncology practices treating hundreds of active chemotherapy patients monthly face significant documentation challenges while managing both active treatment and survivorship care.

Common Documentation Challenges:

• Chemotherapy visits averaging 35-40 minutes, with 10-15 minutes spent on EHR documentation
• Inconsistent CTCAE grading across providers
• Delayed treatment summaries for survivorship care plans
• Provider burnout driven by evening documentation backlogs

Implementation Approach: Oncology practices adopt voice-first AI documentation for chemotherapy visits, follow-up appointments, and survivorship consultations, integrating with oncology-specific EHR systems.

Typical Results After 6 Months:

• Reduce chemotherapy visit documentation from 45-60 minutes to 10-15 minutes
• Standardized toxicity documentation with consistent CTCAE grading across all providers
• Treatment summaries completed within 48 hours instead of 5-7 days
• Evening charting reduced or eliminated for most providers
• Patient satisfaction scores for “provider attentiveness” increase

Oncologists consistently report that during difficult conversations—delivering progression news or discussing end-of-life care—they can maintain eye contact and physical presence while still capturing everything for the record. This represents what compassionate oncology care should look like.

Practices calculate annual time savings equivalent to substantial additional clinical capacity without recruitment costs.

Supportive Care and Survivorship

Cancer care extends beyond chemotherapy. Symptom management, psychosocial support, palliative care discussions, and survivorship planning require compassionate presence and thorough documentation.

During a survivorship visit:

“Patient completed adjuvant chemotherapy six months ago. Now in surveillance phase. Doing well overall but reports persistent fatigue, impacting return to work. Screening for depression negative. Discussed graduated exercise program, referral to occupational therapy for work accommodations. Reviewed surveillance imaging schedule. Mammogram due next month. Patient has questions about genetic testing given family history.”

OrbDoc structures survivorship documentation:

Survivorship Status: 6 months post-completion of adjuvant chemotherapy for stage IIA breast cancer

Current Concerns:

• Cancer-related fatigue: Moderate, persistent, interfering with work resumption
• Depression screening (PHQ-2): Negative
• No evidence of recurrence

Survivorship Care Plan Review:

• Surveillance imaging: Mammogram due [date], next CT chest scheduled [date]
• Endocrine therapy: Continuing tamoxifen, adherent, tolerating well
• Symptom management: Initiated graduated exercise protocol, referral to occupational therapy

Genetic Counseling:

• Patient inquiring about genetic testing given family history (maternal aunt with ovarian cancer at age 52)
• Discussed indications for BRCA testing
• Referral placed to genetic counseling

Psychosocial Support:

• Connected with survivorship support group
• Provided resources for cancer-related fatigue management

Next Appointment: 3 months for surveillance and symptom reassessment

This documentation supports comprehensive survivorship care while ensuring patients feel heard and supported during the transition from active treatment to surveillance.

ROI for Oncology Practices

Oncology practices operate under unique financial and clinical pressures: high-cost medications, complex billing requirements, quality measure reporting, and the emotional toll of cancer care. Voice-first AI documentation delivers measurable returns:

Time Efficiency:

• Substantial reduction in chemotherapy visit documentation time
• Faster treatment summary completion
• Significant reduction in evening documentation burden

Billing and Compliance:

• Improved E/M code support with comprehensive HPI and MDM documentation
• Accurate capture of chemotherapy administration details for billing
• Complete documentation of clinical trial eligibility and monitoring

Quality Metrics:

• Standardized performance status and toxicity grading
• Complete treatment summaries for survivorship care plans (ASCO Quality Oncology Practice Initiative metric)
• Improved documentation of advance care planning discussions

Provider Well-being:

• Reduced administrative burden during emotionally demanding encounters
• Ability to maintain eye contact and physical presence during difficult conversations
• Decreased burnout related to documentation workload

Patient Experience:

• Enhanced perception of provider attentiveness and empathy
• Improved understanding of treatment plans through real-time verbal review
• Reduced wait times as documentation no longer delays clinic flow

For oncology practices, AI medical scribes save substantial clinical hours annually—the equivalent of hiring a full-time advanced practice provider without the recruitment and salary costs.

More importantly, OrbDoc restores what drew providers to oncology: the privilege of guiding patients through cancer treatment with full presence, compassion, and clinical excellence—not divided attention between patient and computer screen.

Ready to restore presence to your oncology practice? Experience OrbDoc with a 14-day trial. Document your next chemotherapy visit by voice and see the difference comprehensive, compassionate care makes when technology supports rather than intrudes on the patient-physician relationship.